Nilka de Jesus-Gonzalez

Learn More
BACKGROUND Hypertension is a toxicity of antiangiogenic therapies and a possible biomarker that identifies patients with superior cancer outcomes. Understanding its mechanism will aid in treatment and could lead to the development of other biomarkers for predicting toxicity and anticancer efficacy. Recent evidence implicates nitric oxide (NO) suppression(More)
Angiogenesis, or the formation of new blood vessels, is essential for solid tumor growth and metastasis, and it is regulated by proangiogenic soluble mediators, including the vascular endothelial growth factor (VEGF). Antiangiogenic drugs that block the VEGF signaling pathway prolong progression-free survival (PFS) in several cancers and are now in broad(More)
  • 1